GenomeMe

GenomeMe specialises in the development and manufacturing of mouse and rabbit immunohistochemistry (IHC) monoclonal antibodies for clinical diagnostic use. Founded in 2017, GenomeMe has rapidly developed a catalogue of over 260 IHC antibodies designed for precision diagnostics. Quality and innovation is reflected in GenomeMe’s in-house development processes, and with 2BScientific enables stringent control over product quality and competitive pricing.
Researchers benefit from GenomeMe’s antibodies developed under ISO 13485:2016 certified quality management systems and CE-IVD compliant performance, ensuring reliable and reproducible results in clinical applications. External quality assessments by NordiQC further validate the performance of GenomeMe’s products, giving researchers confidence in experimental outcomes. Additionally, advanced technologies, including qPCR and Next Generation Sequencing, enable the development of highly specific and sensitive diagnostic tools, crucial for advancing research in molecular pathology.
GenomeMe provide unparalleled value, making cutting-edge diagnostic tools accessible to a broader range of researchers and institutions. GenomeMe's mission to advance precision diagnostics through quality IHC antibodies places 2BScientific as a valuable collaborator in the pursuit of innovative and reliable diagnostic solutions.